MIMEDX Expands Surgical Product Portfolio with the Launch of AMNIOFIX® Thyroid Shields

MARIETTA, Ga., March 05, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the commercial launch of AMNIOFIX Thyroid Shields, a product line extension of the Company's AMNIOFIX dehydrated human amnion/chorion membrane (DHACM) allografts.

GlobeNewsWire • 20 hours ago

MiMedx Group, Inc. (MDXG) Q4 2025 Earnings Call Transcript

MiMedx Group, Inc. (MDXG) Q4 2025 Earnings Call Transcript

Seeking Alpha • Feb 26, 2026

MIMEDX Announces Record Fourth Quarter and Full Year 2025 Operating and Financial Results

Net Sales Grew 27% Year-Over-Year for the Fourth Quarter and 20% for the Full Year Fourth Quarter GAAP Net Income and Earnings Per Share were $15 million and $0.10, Respectively Fourth Quarter Adjusted EBITDA 1 was $29 Million, or 25% of Net Sales Company Estimates 2026 Net Sales in a Range of $340-360 Million Announces $100 Million Share Repurchase Program Authorization Management to Host Conference Call Today, February 25, 2026, at 4:30 PM ET MARIETTA, Ga., Feb. 25, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), today announced operating and financial results for the fourth quarter and full year 2025.

GlobeNewsWire • Feb 25, 2026

MiMedx (MDXG) Q4 Earnings and Revenues Beat Estimates

MiMedx (MDXG) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.07 per share a year ago.

Zacks Investment Research • Feb 26, 2026

MIMEDX to Host Fourth Quarter and Full Year 2025 Operating and Financial Results Conference Call on February 25

MARIETTA, Ga., Feb. 17, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the fourth quarter and full year ended December 31, 2025 after the market close on Wednesday, February 25, 2026. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day.

GlobeNewsWire • Feb 17, 2026

MIMEDX Enters into Exclusive Distribution Agreement with Summit Products Group for Multiple Innovative Surgical & Wound Products

Agreement expands offering to include additional sheet, particulate and flowable products Agreement expands offering to include additional sheet, particulate and flowable products

GlobeNewsWire • Feb 4, 2026

MIMEDX Celebrates 15 Year Anniversary of EPIFIX® and AMNIOFIX®

Industry's Most Studied Placental Allografts Appear in Nearly 100 Clinical and Scientific Publications Industry's Most Studied Placental Allografts Appear in Nearly 100 Clinical and Scientific Publications

GlobeNewsWire • Feb 2, 2026

MIMEDX Enters into Exclusive U.S. Distribution Agreement for RegenKit®-Wound Gel

MARIETTA, Ga., Dec. 22, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced it has entered into an exclusive agreement with Regen Lab USA LLC to distribute their RegenKit®-Wound Gel in the United States.

GlobeNewsWire • Dec 22, 2025

MiMedx (MDXG) Just Flashed Golden Cross Signal: Do You Buy?

From a technical perspective, MiMedx Group, Inc (MDXG) is looking like an interesting pick, as it just reached a key level of support. MDXG's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.

Zacks Investment Research • Nov 17, 2025

MIMEDX Provides Update on EPIEFFECT® Randomized Controlled Trial

Publication of Interim Results and Presentation at Recent Industry Event Demonstrate Clinical Benefit Associated with Use of EPIEFFECT When Compared to Standard of Care (“SOC”)

GlobeNewsWire • Nov 13, 2025